Synopsis
BiVACOR is developing the Total Artificial Heart (TAH) to help treat patients with heart failure.
Implantation of a TAH is a treatment option for patients with end-stage HF who need support while on a heart transplant waiting list or who do not qualify for a transplant. Removal of the native ventricles allows the device to completely replace the function of the native heart.
Heart Failure (HF) is a devastating disease that affects more than 300,000 Australians, and 11 million people in the US and Europe, with an incidence of 1.1 million new cases per year. Furthermore, current growth rates predict a 25% increase in the incidence of HF by 2030.
According to the US National Institutes of Health (NIH), 100,000 patients could immediately benefit from a ventricular assist device (VAD) or total artificial heart (TAH), and the European market is similarly sized. Without intervention, patients with severe HF have a bleak outlook. For these patients, drug therapy is a limited, relatively ineffective option. Although a heart transplant would meet their needs, only 4000 donor hearts are available globally each year.
testimonials
Daniel Timms
CEO, BiVACOR
“OneVentures are a unique, one of a kind investor in the venture capital world. They put tremendous faith in their portfolio companys’ teams to deliver results, and are always on hand to provide pointed advice or step in to fill organizational gaps. BiVACOR has fortunately been part of the OneVentures family for nearly 4 years now, and their unyielding support has allowed our organization to pursue our dream of developing a practical replacement to the failing human heart. Without the OneVentures team, we would not be where we are today!”
